Merck & Company, Inc. Nov 9, 2025 at 10:00 PM UTC OriginalELI5 Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial The original announcement is unavailable.
